Evaluation of IPI-549 Combined With Front-line Treatments in Pts. With Triple-Negative Breast Cancer or Renal Cell Carcinoma
Status: ACTIVE_NOT_RECRUITING
Study type: INTERVENTIONAL
Conditions: Breast Cancer|Renal Cell Carcinoma
Interventions: DRUG: IPI-549 (eganelisib)|DRUG: Atezolizumab|DRUG: nab-paclitaxel|DRUG: Bevacizumab
Sponsor: Infinity Pharmaceuticals, Inc.
Collaborators: Roche Pharma AG